Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Celyad Oncology SA CYAD
$0.58
-$0.04 (-6.49%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
15847915.00000000
-
week52high
3.07
-
week52low
0.46
-
Revenue
0
-
P/E TTM
0
-
Beta
1.72748000
-
EPS
-1.72000000
-
Last Dividend
0.00000000
-
Next Earnings Date
23 мар 2023 г. в 04:00
Описание компании
Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes. The company's preclinical candidate includes CYAD-203, a non-gene edited allogeneic CAR-T candidate to co-express the cytokine interleukin-18 with natural killer group 2D ligands (NKG2D) for the treatment of solid tumors. It has licensing agreement with Novartis International AG regarding the United States patents related to allogeneic CAR-T cells; and research and development collaboration, and license agreements with Horizon Discovery Group plc for the use of its shRNA technology to generate second non-gene-edited allogeneic platform. The company was formerly known as Celyad SA and changed its name to Celyad Oncology SA in June 2020. Celyad Oncology SA was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wells Fargo | Overweight | Overweight | 11 янв 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 06 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 10 мая 2021 г. |
| JonesTrading | Hold | Buy | 26 мар 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 08 дек 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Celyad Oncology to announce full year 2022 financial results and host conference call
GlobeNewsWire
17 мар 2023 г. в 17:01
MONT-SAINT-GUIBERT, Belgium, March 17, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today announced that the Company will report full year 2022 financial and operating results on the evening of Thursday, March 23rd.
What Penny Stocks Trends Can Help You Profit in 2023?
PennyStocks
18 янв 2023 г. в 06:00
How to make money with penny stocks in 2023 The post What Penny Stocks Trends Can Help You Profit in 2023? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Celyad Oncology SA's (CYAD) CEO Michel Lussier on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
05 авг 2022 г. в 09:38
Celyad Oncology SA (NASDAQ:CYAD ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Sara Zelkovic - Director, Communications and Investor Relations Michel Lussier - Interim Chief Executive Officer Charlie Morris - Chief Medical Officer David Georges - Vice President of Finance and Administration Conference Call Participants Raju Prasad - William Blair Operator Greetings and welcome to the Celyad Oncology First Half 2022 Financial Results. At this time, all participants are in a listen-only mode.
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call
GlobeNewsWire
28 июл 2022 г. в 01:05
MONT-SAINT-GUIBERT, Belgium, July 28, 2022 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2022 financial and operating results on the morning of Friday, August 5, 2022.
Celyad Oncology to Announce First Half 2022 Financial Results and Host Conference Call
Business Wire
28 июл 2022 г. в 01:00
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)--Regulatory News: Celyad Oncology SA (Euronext & Nasdaq: CYAD) (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company will report first half 2022 financial and operating results on the morning of Friday, August 5, 2022. Following the press release, Celyad Oncology management will h